Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Abeona Therapeutics (ABEO).
At the recent virtual Annual Meeting, shareholders elected Leila Alland and Vishwas Seshadri as Class 2 directors until the 2027 annual meeting. Additionally, a proposal to double the number of shares reserved for issuance was approved, as was the advisory vote on executive compensation. The appointment of Deloitte & Touche LLP as the independent accounting firm for the upcoming fiscal year was also ratified, reflecting a proactive and forward-looking approach to corporate governance and financial planning by the company’s stakeholders.
See more insights into ABEO stock on TipRanks’ Stock Analysis page.